A open-label, parallel-arm, single-centre, cohort study evaluated the efficacy and safety of ombitasvir/paritaprevir/ritonavir ± ribavirin in patients with genotype-4 hepatitis C virus infection in Qatar

Trial Profile

A open-label, parallel-arm, single-centre, cohort study evaluated the efficacy and safety of ombitasvir/paritaprevir/ritonavir ± ribavirin in patients with genotype-4 hepatitis C virus infection in Qatar

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 May 2016 New trial record
    • 17 Apr 2016 Interim analysis (n=34) presented at The International Liver Congress™ 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top